MXCT
Maxcyte, Inc.Company with tickers: MXCT
CIK
1287098
CUSIP
57777K106
Shares Outstanding
107,121,672
Website
https://www.maxcyte.com
13F Activity (30d)
60 filings
57 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $9,651,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Revenue (ASC 606) | $4,501,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Cost of Revenue | — | ||||
| Gross Profit | $8,082,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Expenses | $14,267,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $3,857,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-6,185,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-4,750,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Cell Engineering Technology Segment | $38,627,000 | $33,026,000 |
By Geography (USD)
| Component | 2024-12-31 | 2025-12-31 |
|---|---|---|
| United States | $25,768,000 | $21,078,000 |
| Non Us | $12,859,000 | $11,948,000 |
By Product & Service (USD)
| Component | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Product | $21,089,000 | $18,691,000 |
| License | $16,412,000 | $12,369,000 |
| Assay And Other Service Revenue | — | $1,966,000 |
| Product And Service Other | $1,126,000 | — |